Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY4214835 · 1 trial · 2 indications
Evaluation of AEs regardless of causality, will be reported in the Reported AEs module
Determination of the radiation dosimetry absorbed dose in body organs and whole-body effective dose
| Arm | Type | Description |
|---|---|---|
| LY4214835 (Cohorts 1 and 2) | EXPERIMENTAL | LY4214835 administered intravenously (IV) |
| Name | Type | Description |
|---|---|---|
| LY4214835 | DRUG | Administered IV |
Inclusion Criteria: * Cohort 1 * Have a radiologically, cytologically, or histologically confirmed diagnosis of cancer * Are treatment-naïve to a systemic cancer therapy, OR have a documented disease progression on standard-of-care treatment (for example, failure of chemotherapy, targeted ther...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 5 | PHASE3 | ACE-536 |
| AbbVie, Inc. | ABBV | 4 | PHASE3 | Navitoclax, Ruxolitinib |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Pelabresib, Ruxolitinib |
| Karyopharm Therapeutics, Inc. | KPTI | 4 | PHASE3 | Selinexor, Ruxolitinib |
| Geron Corporation | GERN | 2 | PHASE3 | Imetelstat |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| Incyte Corporation | INCY | 10 | PHASE2 | Ruxolitinib |
| GSK plc Sponsored ADR | GSK | 2 | PHASE2 | MMB |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | PHASE2 | Elritercept, Ruxolitinib |
| Eli Lilly and Company | LLY | 1 | PHASE1 | LY3410738, Venetoclax, Azacitidine |
| Disc Medicine, Inc. | IRON | 1 | PHASE1 | DISC-0974 |
| Galecto, Inc. | GLTO | 1 | PHASE2 | GB2064 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
| United Therapeutics Corporation | UTHR | 1 | PHASE2 | bomedemstat |
LY4214835 is an investigational small molecule being studied for use in oncology, specifically for the treatment of neoplasms, which are abnormal growths of tissue that can be benign or malignant. It is currently in Phase 1 clinical development.
LY4214835 is being developed by Eli Lilly and Company, a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol LLY. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug.
LY4214835 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials to assess its safety, tolerability, and potential efficacy in humans.
LY4214835 is being studied in a Phase 1 clinical trial registered as NCT07258836. This trial is titled 'A Study of [18F]LY4214835 in Healthy Volunteers and Participants With Cancer' and is currently recruiting participants in the United States.
Yes, LY4214835 is the same as [18F]LY4214835. The [18F] designation indicates that the drug is labeled with the radioactive isotope fluorine-18, which is commonly used in positron emission tomography (PET) imaging to visualize and track the drug in the body.